Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

3 years ago

ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid…

Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape

3 years ago

SOLANA BEACH, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily…

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

3 years ago

Small Pharma shares R&D update on the expansion of its DMT-based portfolio with deuterated DMT candidate and new clinical trials…

TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting

3 years ago

FDA schedules ODAC meeting for April 22, 2022NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today…

Simply Better Brands’ No B.S. Skincare Brand Announces Sponsorship of UFC Champion Julianna Peña

3 years ago

The Mixed Martial Artist, dubbed the Venezuelan Vixen, will collaborate to drive brand awareness as No BS expands omni-channel Julianna…

Clade Therapeutics Announces the Appointment of Derek Hei, Ph.D., as Chief Technology Officer

3 years ago

Dr. Hei has spent over two decades leading manufacturing teams at biotechnology companies and has deep expertise in the cell…

TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol

3 years ago

Patient dosing underway, interim efficacy data on track for second half 2022SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- TRACON…

Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022

3 years ago

●OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β●OT-101 has completed over six clinical trials against solid tumors with good efficacy●OT-101 is…

ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer

3 years ago

MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and…

aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis

3 years ago

Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022.SAN DIEGO, March…